for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arena Pharmaceuticals, Inc.

ARNA.OQ

Latest Trade

51.07USD

Change

-0.12(-0.23%)

Volume

440,329

Today's Range

50.00

 - 

51.73

52 Week Range

31.98

 - 

64.48

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
51.19
Open
51.12
Volume
440,329
3M AVG Volume
9.69
Today's High
51.73
Today's Low
50.00
52 Week High
64.48
52 Week Low
31.98
Shares Out (MIL)
49.83
Market Cap (MIL)
2,550.55
Forward P/E
6.14
Dividend (Yield %)
--

Next Event

Arena Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Arena Pharmaceuticals Q2 Loss Per Share $1.24

Arena Pharmaceuticals Reports First Quarter 2019 Financial Results

Arena Pharmaceuticals Reports Fourth Quarter Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Industry

Biotechnology & Drugs

Contact Info

6154 Nancy Ridge Dr

+1.858.4537200

http://www.arenapharm.com/

Executive Leadership

Tina Susan Nova

Independent Chairman of the Board

Amit D. Munshi

Director, President and Chief Executive Officer

Kevin R. Lind

Executive Vice President and Chief Financial Officer

Steven Wolf Spector

Executive Vice President, General Counsel and Secretary

Vincent E. Aurentz

Executive Vice President and Chief Business Officer

Key Stats

1.80 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.0K

2018

0.0K

2019(E)

0.8K
EPS (USD)

2016

-0.900

2017

-2.770

2018

-0.630

2019(E)

8.340
Price To Earnings (TTM)
4.43
Price To Sales (TTM)
3.13
Price To Book (MRQ)
2.12
Price To Cash Flow (TTM)
4.28
Total Debt To Equity (MRQ)
4.26
LT Debt To Equity (MRQ)
3.96
Return on Investment (TTM)
63.33
Return on Equity (TTM)
61.72

Latest News

Arena Pharma soars on deal with United Therapeutics for hypertension drug

Shares of Arena Pharmaceuticals Inc jumped nearly 30 percent after the drug developer sold rights to develop and sell its hypertension treatment to United Therapeutics Corp, fetching it $800 million in an upfront payment.

BRIEF-Arena Pharmaceuticals Reports Q1 Loss Per Share $0.80

* EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018

BRIEF-Arena Pharmaceuticals To Release Q1 Financial Results And Provide Corporate Update On Tuesday, May 8

* ARENA PHARMACEUTICALS TO RELEASE FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON TUESDAY, MAY 8 Source text for Eikon: Further company coverage:

BRIEF-Arena Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

* ARENA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Arena Pharmaceuticals To Offer 7.5 Mln Shares Of Its Common Stock In An Underwritten Public Offering

* ARENA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Arena Pharma's bowel disease drug meets study goal, shares surge

Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.

BRIEF-Arena Pharmaceuticals Q4 Loss Per Share $0.35

* ARENA PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-Arena Pharma, Everest Medicines Enter Into Development And Commercialization Partnership For Ralinepag And Etrasimod In China

* ARENA PHARMACEUTICALS AND EVEREST MEDICINES ENTER INTO DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP FOR RALINEPAG AND ETRASIMOD IN CHINA

BRIEF-Arena Pharmaceuticals reports Q3 loss per share $0.86

* Arena Pharmaceuticals provides corporate update and reports third quarter 2017 financial results

BRIEF-Arena Pharmaceuticals Q2 loss per share $0.77

* Arena Pharmaceuticals provides corporate update and reports second quarter 2017 financial results

BRIEF-Arena Pharmaceuticals says public offering of 6.25 mln common shares priced at $24 per share

* Arena Pharmaceuticals announces pricing of public offering of common stock

BRIEF-Arena Pharmaceuticals announces proposed public offering of common stock

* Arena Pharmaceuticals announces proposed public offering of common stock

Arena's heart-lung drug succeeds in mid-stage study, shares soar

U.S. drug developer Arena Pharmaceuticals Inc said on Monday its experimental drug for pulmonary arterial hypertension (PAH), a rare but deadly lung disease, met the main goal in a mid-stage study.

BRIEF-Arena Pharmaceuticals Inc's board increased size of board from nine directors to ten directors

* Arena Pharmaceuticals Inc - on June 13, 2017, board of directors increased size of board from nine directors to ten directors Source text:(http://bit.ly/2rAYXbA) Further company coverage:

BRIEF-Arena Pharmaceuticals says shareholders and board approve reverse stock split

* Arena Pharmaceuticals announces shareholders and board of directors approve reverse stock split

BRIEF-Arena Pharmaceuticals reports Q1 loss per share $0.09

* Arena Pharmaceuticals provides corporate update and reports first quarter 2017 financial results

BRIEF-Great Point Partners reports 9.75 pct passive stake in Arena Pharmaceuticals

* Great Point Partners LLC reports 9.75 percent passive stake in Arena Pharmaceuticals Inc as of April 18 - SEC filing Source: (http://bit.ly/2pdzPcX) Further company coverage:

BRIEF-Arena Pharmaceuticals prices 60 mln shares of common stock at price of $1.15/share

* Arena Pharmaceuticals announces pricing of public offering of common stock

BRIEF-Arena Pharmaceuticals announces proposed public offering of common stock

* Arena Pharmaceuticals announces proposed public offering of common stock Source text for Eikon: Further company coverage:

BRIEF-Arena Pharma qtrly net income $38.3 mln or $0.16 per share

* Arena pharmaceuticals provides corporate update and reports fourth quarter and full-year 2016 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up